Bronfman E.L. Rothschild L.P. Sells 2,278 Shares of Allergan plc (AGN)
Bronfman E.L. Rothschild L.P. lowered its stake in Allergan plc (NYSE:AGN) by 44.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,899 shares of the company’s stock after selling 2,278 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Allergan were worth $474,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Auxier Asset Management raised its stake in shares of Allergan by 0.6% in the second quarter. Auxier Asset Management now owns 8,010 shares of the company’s stock worth $1,947,000 after buying an additional 50 shares during the period. North Star Asset Management Inc. raised its stake in shares of Allergan by 0.3% in the second quarter. North Star Asset Management Inc. now owns 26,955 shares of the company’s stock worth $6,552,000 after buying an additional 80 shares during the period. WFG Advisors LP raised its stake in shares of Allergan by 20.9% in the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after buying an additional 137 shares during the period. Stonebridge Capital Advisors LLC raised its stake in shares of Allergan by 1.4% in the second quarter. Stonebridge Capital Advisors LLC now owns 11,413 shares of the company’s stock worth $2,774,000 after buying an additional 155 shares during the period. Finally, Rikoon Group LLC raised its stake in shares of Allergan by 9.4% in the second quarter. Rikoon Group LLC now owns 1,802 shares of the company’s stock worth $438,000 after buying an additional 155 shares during the period. 79.76% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently commented on AGN shares. Zacks Investment Research downgraded Allergan from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Deutsche Bank set a $251.00 price objective on Allergan and gave the stock a “buy” rating in a research note on Tuesday, October 17th. TheStreet downgraded Allergan from a “c-” rating to a “d+” rating in a research note on Monday, December 4th. Morgan Stanley set a $200.00 target price on Allergan and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Finally, Credit Suisse Group set a $243.00 target price on Allergan and gave the stock an “outperform” rating in a research report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. Allergan presently has an average rating of “Buy” and an average price target of $227.23.
Allergan (NYSE:AGN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the consensus estimate of $4.74 by $0.12. The business had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. Allergan had a positive return on equity of 8.28% and a negative net margin of 26.32%. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the business posted $3.90 EPS. equities research analysts expect that Allergan plc will post 15.56 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.81%. The ex-dividend date is Tuesday, February 27th. This is a boost from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is currently -23.35%.
In related news, Chairman Brent L. Saunders bought 4,600 shares of the company’s stock in a transaction dated Wednesday, December 6th. The stock was purchased at an average price of $164.74 per share, for a total transaction of $757,804.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Chris W. Bodine bought 3,030 shares of the company’s stock in a transaction dated Thursday, December 7th. The stock was bought at an average price of $164.77 per share, with a total value of $499,253.10. The disclosure for this purchase can be found here. Insiders have acquired a total of 17,630 shares of company stock valued at $2,890,057 in the last 90 days. 0.36% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Bronfman E.L. Rothschild L.P. Sells 2,278 Shares of Allergan plc (AGN)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/02/14/bronfman-e-l-rothschild-l-p-sells-2278-shares-of-allergan-plc-agn.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.